1. Introduction {#sec1-molecules-24-02276}
===============

Lipid mediators have drawn much attention in clinical studies because they are a family of molecules that play a key role in the progression of inflammation and metabolic disorders \[[@B1-molecules-24-02276]\]. They exhibit a large number of physiological effects in almost every organ system because of highly coordinated active processes including cellular signaling and transcription factors regulation, modulation of metabolic pathways and inflammation resolution, \[[@B2-molecules-24-02276]\]. The production of these bioactive compounds is mediated by cyclooxygenases, lipoxygenases, cytochrome P450 mono- oxygenases, and non-enzymatic pathways \[[@B3-molecules-24-02276]\] from the main ω-6 and ω-3 PUFAs as it is shown in [Figure 1](#molecules-24-02276-f001){ref-type="fig"}a,b. A very large number of isomeric compounds from different families can be produced. Specific examples include the families of PGs, IsoPs, TXs, and LTs which have been described as pro-inflammatory substances \[[@B1-molecules-24-02276],[@B4-molecules-24-02276]\]. The most studied compounds derived from ARA are PGE~2~, PGF~1α~, PGF~2α~, TXA~2~ and 8iso-PGF~2α~, which have been associated with the chronic inflammatory stage of hypercholesterolemia, liver cirrhosis, myocardial reperfusion, type-2 diabetes, obesity, atherosclerosis, cancer, and CVD \[[@B5-molecules-24-02276],[@B6-molecules-24-02276],[@B7-molecules-24-02276],[@B8-molecules-24-02276]\]. On the other hand, the corresponding metabolites produced from EPA and DHA have been suggested as less harmful compounds than the ω-6 ones \[[@B9-molecules-24-02276],[@B10-molecules-24-02276]\]. Oxygenated lipid mediators derived from EPA and DHA, have been suggested one of the most efficient mechanisms to stop inflammation in a highly coordinated, active process \[[@B11-molecules-24-02276]\]. Several works indicates that these mediators can resolve acute inflammatory responses with minimal damage to the surrounding tissue in a variety of inflammation situations \[[@B12-molecules-24-02276],[@B13-molecules-24-02276]\]. Molecules like LXs \[[@B14-molecules-24-02276]\], epoxides \[[@B15-molecules-24-02276]\], and the recently discovered Rvs, PDs, and MaRs \[[@B16-molecules-24-02276]\]. have been associated with the resolution of inflammation in CVD \[[@B6-molecules-24-02276]\], arthritis \[[@B17-molecules-24-02276]\], asthma \[[@B18-molecules-24-02276]\], cancer \[[@B19-molecules-24-02276],[@B20-molecules-24-02276]\], or Alzheimer \[[@B21-molecules-24-02276],[@B22-molecules-24-02276]\].

The simultaneous analysis of the different families is a tough challenge, mainly because of their low physiological levels and the low stability \[[@B23-molecules-24-02276]\], the matrix background interferences, and the large number of isomers with similar physicochemical properties and mass spectra that hinder their chromatography resolution and MS/MS identification \[[@B24-molecules-24-02276]\]. Therefore, a highly sensitive and selective analytical procedure is essential to comprehensively study these lipid classes. Mass spectrometry has played a central role in quantitative assays for most of lipid mediators but also in their structural elucidation.

While some progress has been made on the decomposition behavior of ω-6 metabolites, there is a great deal more to understand ω-3 metabolism. For many years, GC-MS was the method of choice for lipids mediators \[[@B25-molecules-24-02276]\]; nevertheless, the widespread LC-MS coupled with high-sensitivity ESI has provided a new approach for quantification, minimizing sample preparation requirements and particularly avoiding derivatization reactions \[[@B26-molecules-24-02276]\]. Commonly, LC-MS/MS procedures follow MRM targeted analysis. Methods available in literature range from the simultaneously analysis of a few compounds \[[@B27-molecules-24-02276],[@B28-molecules-24-02276]\] to more than one hundred \[[@B29-molecules-24-02276],[@B30-molecules-24-02276],[@B31-molecules-24-02276]\]. Although these assays are sensitive and selective and cover a large number of metabolites, they are limited due to the trade-off between the decreases of sensitivity and the increase of the number of monitored compounds. In addition, MRM is limited to the analysis of a specific targeted group of compounds that operator must pre-define prior to the analysis. Therefore, the method is not suitable for a screening of the whole family of lipid mediators in biological samples unless a big number of expensive analytical standards are used to stablish the MS/MS transitions list.

Non-targeted LC-MS/MS strategies register the full mass spectra of each group of compounds having the same parent mass. Then, this method favors the structural elucidation of metabolites enhancing the identification of co-eluting isomers. Moreover, this procedure allows the identification of many lipid mediators based on the study of fragmentation patterns without preselecting a group of compounds that might be or not in samples. Few works proposing screening methods of MS/MS have been found in literature to analyze lipid mediators. One of them was performed by Masoodi et al. \[[@B24-molecules-24-02276]\] who validated an analytical methodology for the screening of lipid mediators combining the high mass resolution authority of an Orbitrap instrument and the study of MS/MS transitions. In our study, we achieved good identifications by using a LIT and suggested new specific transitions to identify lipid mediators.

The aim of this research was to develop a sensitive and selective non-targeted MS/MS method that allows the simultaneous screening of more than 100 lipid mediators in a single run. The procedure is based on the exhaustive interpretation of the mass spectra obtained. Firstly, SPE extraction of analytes from plasma and adipose tissue was carried out by and the procedure was validated for most of the different families of lipid mediators. 65 analytical standards of the representative metabolites were used for recovery experiments. Secondly, the mass spectra of the main ω-6 and ω-3 lipid mediators representative of the different families were exhaustive interpreted in order to systematize a pattern of diagnostic fragments for each compound. Then, a 24 min LC-MS/MS method operating in full scan mode and including the parent mass of the main families of compounds was optimized. Chromatographic gradient and mass spectrometry parameters were set for this representative group of 65 analytical standards. Finally, biological samples were analyzed and unknown peaks were tentatively identified matching specific MS/MS transitions with fragmentation patterns previously selected. Identifications were further validated by using analytical standards. This work provides an extensive interpretation and compilation of distinctive fragmentation patterns of lipid mediators that allows the use of non-targeted MS/MS strategies for the non-limited screening of biological samples.

2. Results and Discussion {#sec2-molecules-24-02276}
=========================

2.1. SPE-LC-MS/MS Validation {#sec2dot1-molecules-24-02276}
----------------------------

The complete SPE-LC-MS/MS methodology applied for the extraction and analysis of lipid mediators. was validated with 65 standards representative of the main groups of compounds. The retention times, the selected MS/MS transitions, R^2^ linearity, repeatability, reproducibility, LODs, and LOQs of these 65 analytical standards are summarized in [Table 1](#molecules-24-02276-t001){ref-type="table"}.

The linear dynamic range of response was observed between 1 ng/mL and 1000 ng/mL for each compound. R^2^ values were higher than 0.99 for most compounds. LOD and LOQ values ranged between 0.01 to 17.65 ng/mL and 0.03 to 58.84 ng/mL, respectively, and these values were in agreement with those previously reported in the literature \[[@B16-molecules-24-02276],[@B28-molecules-24-02276],[@B32-molecules-24-02276]\]. The instrumental intra-day repeatability and inter-day reproducibility at the low, intermediate and high concentration ranges (*n* = 4) showed acceptable precision, with values below 15 %RSD for almost all compounds.

Finally. [Table 2](#molecules-24-02276-t002){ref-type="table"} summarizes the repeatability of the entire optimized method, the global recovery, SPE recovery and matrix effects for spiked samples. The %RSD obtained in the different set of recovery experiments ranged between 0.01--21 in plasma and 0.4--67 in adipose tissue and they were slightly higher than instrumental %RSD. Thus, the precision of the entire protocol is mainly controlled by the sample extraction rather than by the mass analyzer. Global recoveries ranged between 7--489% in plasma and 18--442% in adipose tissue and recoveries of the SPE step were around 100 ± 15% for most of the compounds in plasma and were lower in adipose tissue, ranging between 40--115%. The main parameter that affected the global recovery of the method was the matrix effect. It ranged between 10--494% in plasma samples and between 21--580% in adipose tissue. There might be multiple reasons for the loss/gain of signal in the mass spectrometer. Among the main causes stand out the ion suppression and the overproduction of the \[M-H\]^-^ precursor ions of analytes in the ESI source due to co-eluting substances from the matrix. Matrix effects were considerable for some metabolites eluting in the last part of the chromatography.

2.2. Fragmentation Patterns Through the Analysis of Mass Spectra of Lipid Mediators {#sec2dot2-molecules-24-02276}
-----------------------------------------------------------------------------------

Here it is presented an extensive study of the MS/MS spectra of over 100 ARA. EPA and DHA lipid mediator that allowed determining specific fragmentation patterns useful for identification purposes. Most of MS/MS spectra and/or stereochemical structure of compounds were obtained from the LIPID MAPS database (<https://www.lipidmaps.org>). In the next paragraphs, fragmentation patterns for the different families of lipid mediators are discussed and specific cleavages aimed to identify the different chemical isomers are suggested. Most of the collision-induced decompositions suggested have been also discussed by previous published works. Specially, those compounds derived from the metabolism of ARA \[[@B33-molecules-24-02276]\]. However, to the best of our knowledge, illustrative fragmentations of EPA and DHA derivatives some are innovatively proposed in this work. In addition to the study of mass spectra, the main difficulties in the identification of some isomers are also pointed out, as are common false positive identifications and so on.

### 2.2.1. Monohydroxides {#sec2dot2dot1-molecules-24-02276}

A common fragmentation pattern was observed for monohydroxides of ARA (HETEs), EPA (HEPEs) and DHA (HDoHEs), that was independent from the number of carbons of the PUFA precursor. MS/MS spectra showed common product ions of high intensity that involved the cleavage of the hydroxyl group (−18 *m/z* units = loss of H~2~O) and further loss of 44 *m/z* units (CO~2~) \[[@B34-molecules-24-02276]\]. Murphy et al. \[[@B33-molecules-24-02276]\] have suggested that ARA hydroxides produce a type of carbon-carbon cleavage with retention of the charge in the carboxyl group stabilized by resonance due to the high unsaturation of the molecules. These cleavages gave rise to several common product ions for all isomers. The specific transitions that allowed differentiating these HETEs originated from the cleavage of a carbon-carbon bond adjacent to the hydroxyl group (α-hydroxy cleavage) at the allylic position and a transfer of one proton to the unsaturated site \[[@B35-molecules-24-02276]\]. We have suggested the same behavior for EPA and DHA hydroxides on the basis of the analyzed spectra and similarities with chemical structures of ARA hydroxides. The *m/z* of the resulting aldehyde and/or ketone depended on the position of the hydroxyl group and thus it allowed unambiguous determination of the regioisomers. The aldehyde also produced a specific fragment by a concomitant loss of 28 *m/z* units (loss of CO). The fragmentation pattern of 8-HETE, 12-HEPE, and 17-HDoHE as an example of hydroxides from each group are explained in detail in [Figure 2](#molecules-24-02276-f002){ref-type="fig"}. Similar patterns were found for the other studied regioisomers whose spectra were available at LIPID MAPS. A total of eight HETEs, seven HEPEs and ten HDoHEs were analyzed and the corresponding fragmentations are shown in [Supplementary Materials S1](#app1-molecules-24-02276){ref-type="app"}.

### 2.2.2. Hydroperoxides {#sec2dot2dot2-molecules-24-02276}

The spectra of HpETEs, HpEPEs and HpDoHEs ([Figure 3](#molecules-24-02276-f003){ref-type="fig"} and [Supplementary Materials S2](#app1-molecules-24-02276){ref-type="app"}) showed a common pattern of fragmentation based on the highly reactivity of the functional group with nearby double bonds. The characteristic fragmentation suggested was very similar to the analogous hydroxides and independent from the number of carbons of the PUFA precursor. For regioisomers without spectra available in database, specific fragments were hypothesized based on the stoichiometric structure ([Table 3](#molecules-24-02276-t003){ref-type="table"}). The loss of two molecules of H~2~O, CO~2~, and carbon-carbon bond cuts produced a sort of common fragments between isomers. The location of the hydroperoxy group in the chain determined the formation of characteristic fragments that allowed differentiating the isomers of each PUFA. As for corresponding hydroxides, the α-hydroxy cleavage of carbon-carbon bond resulted into an aldehyde with characteristic *m/z* and further loss of CO. Generally, most intense fragments were produced by the α-hydroxy cleavage with stabilization of the hydroperoxyl group in a diol structure, and then the loss of H~2~O and formation of an enol stabilized by resonance. A total of seven hydroperoxide spectra were studied and specific fragments were suggested for another seventeen isomers.

### 2.2.3. Prostaglandins {#sec2dot2dot3-molecules-24-02276}

The analysis of twelve spectra of type-2 prostaglandins from ARA and type-3 from EPA revealed similar decomposition pathway behavior. Non-specific cleavages that allowed distinguishing isomers were found according to the stereochemical structure of molecules that generally consists of a cyclopentane ring and two side chains with carboxylic and hydroxy groups, respectively.

Intense product ions resulted from the subsequent losses up to three molecules of H~2~O and losses of CO~2~ from intermediate ions that were produced by the cleavage of the carboxylic group and stabilization of the charge by resonance of the hydroxyl with nearby double bonds. The carbon-carbon cleavage in the vinylic position of the C-15 hydroxyl produced a neutral hexenal compound by a proton transfer and several characteristic fragments with additional losses of H~2~O, CO~2~ and transfer of protons. An intermediate carbanion produced by the α-hydroxy cleavage may produce the rupture of the ring and stabilization by conjugate dienes of the corresponding fragment. These findings agree with previous published descriptions of the fragmentation of the prostaglandins family \[[@B35-molecules-24-02276],[@B36-molecules-24-02276],[@B37-molecules-24-02276]\]. It is possible to unambiguously differentiate up to six groups of prostaglandins based on the parent mass *m/z*: 367, 353, 351, 349, 333 and 331. However, only a good chromatographic resolution of the peaks between isomers with the same *m/z* may lead to their differentiation due to their fragmentations are virtually identical. [Figure 4](#molecules-24-02276-f004){ref-type="fig"} and [Supplementary Materials S3](#app1-molecules-24-02276){ref-type="app"} graphically explain some examples of prostaglandin fragmentation patterns.

### 2.2.4. Resolvins, Protectins and Maresins {#sec2dot2dot4-molecules-24-02276}

Recent experiments have uncovered that EPA and DHA serve as precursors for the production of potent bioactive mediators called resolvins, protectins and maresins \[[@B38-molecules-24-02276]\]. The fragmentations of RvD~1~, RvE~1~ and PD~1~ have been described in detail in [Figure 5](#molecules-24-02276-f005){ref-type="fig"}. Common fragments were produced due to the higher unsaturation of the molecules and the number of hydroxy functional groups (up to 3) that gave rise to many losses of H~2~O and CO~2~. Specifically. the α-cleavage of hydroxyl determined several characteristic fragments as suggested by Serhan et al. \[[@B39-molecules-24-02276]\]. Generally, the carbon-carbon bond was cleaved in the vinylic position when the hydroxyl was more proximal to the end of the carbon chain; however, it was cleaved in allylic position when proximal to the carboxylic group giving an aldehyde ion. Further losses of H~2~O and CO~2~ were produced from intermediate fragments too. Nevertheless, due to the novelty of these molecules, all isomers have not been widely characterized and spectra were not available, so we have suggested possible fragments for identification of series-D and E resolvins and MaR-1 based on the chemical structures and a similar behavior of the isomers in the decomposition pathways ([Supplementary Materials S4](#app1-molecules-24-02276){ref-type="app"}). The fragmentation proposed for MaR-1 was in agreement with the mass characterization of in vitro studies reported by Dalli et al. \[[@B40-molecules-24-02276]\].

### 2.2.5. Leukotrienes, Lipoxins and Dihydroxides {#sec2dot2dot5-molecules-24-02276}

Another thirteen di-/trihydroxyeicosanoids derived from ARA and EPA have been studied and classified into four groups: LTs, LXs, DiHETEs and DiHETrEs. A common fragmentation pattern was observed, as described for resolvins and protectins, that produced common ions between isomers (losses of H~2~O and CO~2~). MS/MS spectra showed specific transitions depending on the location of hydroxy groups that were originated from α-hydroxy cleavages of adjacent carbon-carbon bonds and concomitant losses of H~2~O, CO~2.~ and CO. The same trend as for resolvins and protectins was observed, with carbon-carbon cleavages generally occurring in the vinylic position of the hydroxyl located close to the terminal of the chain. On the contrary, the α-hydroxy cleavages proximal to the carboxylic group usually occurred in the allylic position. Results were in agreement with the MS/MS fragmentation pathways suggested by Murphy et al. \[[@B33-molecules-24-02276]\] and Wheelan et al. \[[@B41-molecules-24-02276]\].

Detailed decomposition pathways are shown in [Figure 6](#molecules-24-02276-f006){ref-type="fig"} and [Supplementary Materials S5](#app1-molecules-24-02276){ref-type="app"}. The unambiguous identification of polyhydroxy compounds resulted difficult, due to the fact they may produce common fragments as other eicosanoids with the same parent mass ion. That is the case of DiHETEs and HpHETEs (*m/z* 335), LXA~4~-B~4~ and some TXs and PGs (*m/z* 351), LXA~5~ and resolvins and some prostaglandins (*m/z* 351). It is also important to note that DiHETEs may produce similar fragmentation patterns than derived HEPEs after the initial loss of H~2~O. However, the different parent mass allows distinguishing without doubts between these two groups of similar eicosanoids.

### 2.2.6. Epoxy and Oxo-derivatives {#sec2dot2dot6-molecules-24-02276}

As described by Murphy et al. \[[@B33-molecules-24-02276]\], epoxy derivatives of ARA (EpETrEs) showed fragmentation patterns very close to those of HETEs and keto derivatives of ARA showed similar fragmentations as HEPEs. In the case of EpETrEs, the spectra generally resulted in a mixture of the two spectra from HETEs with functional groups in the same locations as the epoxy group ([Figure 7](#molecules-24-02276-f007){ref-type="fig"} and [Supplementary Materials S6](#app1-molecules-24-02276){ref-type="app"}). Distinguishing some isomers from both isobaric groups---EpETrEs and HETEs---may be challenging if they are not chromatographically resolved because they have the same parent mass *m/z* and share most of the intense transitions. However, the epoxy LTA~4~ with one more unsaturation in the chain could be easily differentiated from HETEs and EpETrEs due to the lower *m/z* of the parent ion. The identification of some compounds from oxoETEs and HEPEs may result even more complicated without good chromatography resolution because they have the same parent mass and produce exactly the same MS/MS transitions. The main cleavages from ARA oxoETEs in [Figure 8](#molecules-24-02276-f008){ref-type="fig"} are explained. Powell et al. \[[@B42-molecules-24-02276]\] and MacMillan et al. \[[@B43-molecules-24-02276]\] have also studied fragmentations from some oxo-derivatives of ARA. In a similar manner, the MS/MS spectra of several keto-PGs showed the same fragments as the corresponding PGs ([Figure 9](#molecules-24-02276-f009){ref-type="fig"} and [Supplementary Materials S7](#app1-molecules-24-02276){ref-type="app"}). However, the different parent mass allowed the unambiguous identification between both families.

### 2.2.7. Thromboxanes {#sec2dot2dot7-molecules-24-02276}

Finally, the group of thromboxanes from ARA (series 2) and EPA (series 3) showed common losses of subsequent H~2~O molecules and CO~2.~ Thromboxanes are eicosanoids structurally characterized by a six-member ring fused between C-8 and C-12 of the fatty acid. Margalit et al. \[[@B44-molecules-24-02276]\] have suggested that the characteristic rupture of the ring becomes more interesting for identification of these compounds. This cleavage produces an unstable diol structure that easily loses a H~2~O molecule and derived to a more stable aldehyde \[[@B45-molecules-24-02276]\]. The spectra and fragmentation patterns of TXB~3~ and TXB~2~ are shown in [Figure 10](#molecules-24-02276-f010){ref-type="fig"} and [Supplementary Materials S8](#app1-molecules-24-02276){ref-type="app"} and characteristic cleavages are suggested for TXA~2~ which spectrum was not available.

2.3. Tentative Identifications in Samples and Validation {#sec2dot3-molecules-24-02276}
--------------------------------------------------------

Once the extraction and determination procedures were validated, and fragmentation patterns were studied, we tentatively identified lipid mediators in samples of plasma and adipose tissue. Firstly, compounds were searched according to the *m/z* of parent ion and suggested specific fragmentations. For the highly unstable hydroperoxides, the ionization process provoked the loss of H~2~O in the source, then, the parent ion minus *m/z* 18 was also considered as the parent ion. As it was pointed out before, the large number of isomers makes it difficult to establish a single transition for every compound that leads to unambiguous identifications. A total of 35 compounds in adipose tissue and 30 in plasma were tentatively identified using the diagnostic fragmentation patterns.

Next, the identification was validated using a set of standards. Up to 27 hypothetical identifications were validated in adipose tissue and 25 in plasma. Results showed a confirmation rate of our hypotheses of 85 and 88% in adipose tissue and plasma, respectively (4 and 3 proposed identifications failed, respectively).

Specifically, the presence of nine isomers in adipose tissue and seven in plasma from the family of HEPEs and oxoETEs was observed on the basis of the screening analysis of *m/z* 317. We tentatively identified 18-HEPE, 15-HEPE, 12-HEPE, 11-HEPE, 5-HEPE and 12-oxoETE in both samples and their presence was confirmed by using commercial standards. Specific and common cleavages were found for these compounds according to the rules described above. In addition, an increase in the retention time of hydroxides was observed when the position of hydroxyl was more proximal to the carboxylic group. This fact may be explained by a decrease in the polarity of the molecule. However, there were exceptions to this rule between 11-HEPE and 12-HEPE, 11-HETE and 12-HETE and 13-HDoHE and 14-HDoHE in agreement with Massey et al. \[[@B1-molecules-24-02276]\]. 9-HEPE was suggested in adipose tissue although it was not validated. The isomers 5-oxoETE in both samples and 15-oxoETE in adipose were suggested. However, validation experiments showed non-coincidence of the retention times between standards and the hypothetical peaks.

Similarly, the presence of 15-HETE, 12-HETE, 11-HETE and 14.15-EpETE in both samples was suggested based on the screening analysis of *m/z* 319. 11.12-EpETE was only suggested in adipose tissue and 20-HETE in plasma. In addition, one peak was found in both samples leading to theoretical identification of 5.6-EpETE or 5-HETE. They cannot be unambiguously identified without retention time information due to similarities in the mass spectra and specific transitions. The use of 5-HETE standard confirmed the absence of this compound in samples. Additionally, it was observed that epoxy and hydroxy isomers with concurrent positions of functional groups did not co-elute under our LC conditions. Therefore a peak attributed either to 5-HETE or 5.6-EpETE was tentatively identified and then validated as the epoxy isomer.

Special attention was required for hydroperoxides from DHA (HpDoHE) (*m/z* 359), EPA (HpEPE) (*m/z* 333), and ARA (HpETE) (*m/z* 335). These compounds were found to display higher sensitivity using the ratios *m/z* 341, *m/z* 315 and *m/z* 317 as parent mass filter, respectively. In spite of the low-energy ionization used, hydroperoxides may lose a H~2~O molecule in the ESI source due to the low stability of the hydroperoxy group. Therefore, specific transitions for these compounds were searched for in the chromatogramf using both "parent mass" ratios. We could not confirm the hypothesis of the presence of HpDoHEs and HpETEs based on common and specific transitions. However, the use of commercial 17-HpDoHE showed its presence in both samples although it had not been previously hypothesized. The presence of 12-HpEPE was suggested and further validated in plasma.

Regarding DHA hydroxides, the analysis of *m/z* 343 showed a hypothetical identification of eight isomers in adipose tissue and six isomers in plasma based on specific transitions. Standards validation confirmed four hydroxides in adipose and three in plasma. No false identifications were seen in this group. In the same way. 335 *m/z* was analyzed searching for DiHETEs from ARA. Six isomers were tentatively found in adipose tissue and five in plasma, from which two were confirmed and one rejected by using standards. Then, the presence of PGE~2~/PGD~2~, ARA, EPA and DHA was suggested in both samples by analyzing *m/z* 351, 303, 301 and 327 parent mass ions, respectively, and the hypotheses were confirmed. Finally, 14.15-DiHETrE was hypothesized in adipose tissue based on 337 *m/z* screening and it was validated.

Seven other *m/z* ratios were also detected but their fragmentation pattern could not be assigned to any of the groups studied (624, 375, 369, 367, 353, 349 and 331). Results for tentative identifications and validations are summarized in [Table 4](#molecules-24-02276-t004){ref-type="table"}, along with information about specific transitions.

3. Experimental Section {#sec3-molecules-24-02276}
=======================

3.1. Chemicals {#sec3dot1-molecules-24-02276}
--------------

Thromboxane B~3~ (TXB~3~), prostaglandin D~3~ (PGD~3~), prostaglandin E~3~ (PGE~3~), prostaglandin D~2~ (PGD~2~), prostaglandin E~2~ (PGE~2~), prostaglandin B~2~ (PGB~2~), prostaglandin J~2~ (PGJ~2~), resolvin D~1~ (RvD~1~), resolvin D~2~ (RvD~2~), maresin R~1~ (MaR~1~), protectin D~x~ (PD~x~, 10(*S*),17(*S*)-dihydroxy-4*Z*,7*Z*,11*E*,13*Z*,15*E*,19*Z*-docosahexaenoic acid), leukotriene B~4~ (LTB~4~), leukotriene C~4~ (LTC~4~), isoprostane F~2α~ (8isoPGF~2α~), isoprostane F~3α~ (8isoPGF~3α~), 15-HpEPE (15(*S*)-hydroperoxy-5*Z*,8*Z*,11*Z*,13*E*,17*Z*-eicosapentaenoic acid), 12-HpEPE (12(*S*)-hydroperoxy- 5*Z*,8*Z*,10*E*,14*Z*,17*Z*-eicosapentaenoic acid), 15-HpETE (15(*S*)-hydroperoxy-5*Z*,8*Z*,11*Z*,13*E*- eicosatetraenoic acid), 12-HpETE (±12-hydroperoxy-5*Z*,8*Z*,10*E*,14*Z*-eicosatetraenoic acid), 5-HpETE (5(*S*)-hydroperoxy-6*E*,8*Z*,11*Z*,14*Z*-eicosatetraenoic acid), 17-HpDoHE (17(*S*)-hydroperoxy- 4*Z*,7*Z*,10*Z*,13*Z*,15*E*,19*Z*-docosahexaenoic acid), 18-HEPE (±18-hydroxy-5*Z*,8*Z*,11*Z*,14*Z*,16*E*-eicosa- pentaenoic acid), 15-HEPE (±15-hydroxy-5*Z*,8*Z*,11*Z*,13*E*,17*Z*-eicosapentaenoic acid), 12-HEPE (±12-hydroxy-5*Z*,8*Z*,10*E*,14*Z*,17*Z*-eicosapentaenoic acid), 11-HEPE (±11-hydroxy-5*Z*,8*Z*,12*E*,14*Z*, 17*Z*-eicosapentaenoic acid), 5-HEPE (±5-hydroxy-6*E*,8*Z*,11*Z*,14*Z*,17*Z*-eicosapentaenoic acid), 17,18-DiHETE (±17,18-dihydroxy-5*Z*,8*Z*,11*Z*,14*Z*-eicosatetraenoic acid), 17,18-EpETE (±17,18-epoxy- 5*Z*,8*Z*,11*Z*,14*Z*-eicosatetraenoic acid), 11,12-EpETE (±11,12-epoxy-5Z,8Z,14Z,17Z-eicosatetraenoic acid), 14,15-EpETE (±14,15-epoxy-5*Z*,8*Z*,11*Z*,17*Z*-eicosatetraenoic acid), 8,9-EpETE (±8,9-epoxy- 5*Z*,11*Z*,14*Z*,17*Z*-eicosatetraenoic acid), 20-HETE (±20-hydroxy-5*Z*,8*Z*,11*Z*,14*Z*-eicosatetraenoic acid), 15-HETE (±15-hydroxy-5*Z*,8*Z*,11*Z*,13*E*-eicosatetraenoic acid), 12-HETE (±12-hydroxy-5*Z*,8*Z*,10*E*, 14*Z*-eicosatetraenoic acid), 11-HETE (±11-hydroxy-5*Z*,8*Z*,12*E*,14*Z*-eicosatetraenoic acid), 5-HETE (±5-hydroxy-6*E*,8*Z*,11*Z*,14*Z*-eicosatetraenoic acid), 14,15-DiHETE (±14,15-dihydroxy-5*Z*,8*Z*,11*Z*, 17*Z*-eicosatetraenoic acid), 5,15-DiHETE (5(*S*),15(*S*)-dihydroxy-6*E*,8*Z*,10*Z*,13*E*-eicosatetraenoic acid), 5,6-DiHETE (±5,6-dihydroxy-8*Z*,11*Z*,14*Z*,17*Z*-eicosatetraenoic acid), 11,12-DiHETrE (±11,12- dihydroxy-5*Z*,8*Z*,14*Z*-eicosatrienoic acid), 11,12-EpETrE (±11,12-epoxy-5*Z*,8*Z*,14*Z*-eicosatrienoic acid), 8,9-DiHETrE (±8,9-dihydroxy-5*Z*,11*Z*,14*Z*-eicosatrienoic acid), 8,9-EpETrE (±8,9-epoxy- 5*Z*,11*Z*,14*Z*-eicosatrienoic acid), 14,15-DiHETrE (±14,15-dihydroxy-5*Z*,8*Z*,11*Z*-eicosatrienoic acid), 14,15-EpETrE (±14,15-epoxy-5*Z*,8*Z*,11*Z*-eicosatrienoic acid), 5,6-DiHETrE (±5,6-dihydroxy-8*Z*,11*Z*, 14*Z*-eicosatrienoic acid), 5,6-EpETrE (±5,6-epoxy-8*Z*,11*Z*,14*Z*-eicosatrienoic acid), 17-HDoHE (±17-hydroxy-4*Z*,7*Z*,10*Z*,13*Z*,15*E*,19*Z*-docosahexaenoic acid), 14-HDoHE (14(S)-hydroxy-4*Z*,7*Z*, 10*Z*,12*E*,16*Z*,19*Z*-docosahexaenoic acid), 11-HDoHE (±11-hydroxy-4*Z*,7*Z*,9*E*,13*Z*,16*Z*,19*Z*- docosahexaenoic acid), 4-HDoHE (±4-hydroxy-5*E*,7*Z*,10*Z*,13*Z*,16*Z*,19*Z*-docosahexaenoic acid), 19,20-DiHDPA (±19,20-dihydroxy-4*Z*,7*Z*,10*Z*,13*Z*,16*Z*-docosapentaenoic acid), 19,20-EDP (±19,20- epoxy-4*Z*,7*Z*,10*Z*,13*Z*,16*Z*-docosapentaenoic acid), 7(*S*)-17(*S*)dihydroxy-8*E*,10*Z*,13*Z*,15*E*,19*Z*- docosapentaenoic acid), 10,11-EDP (±10,11-epoxy-4*Z*,7*Z*,13*Z*,16*Z*,19*Z*-docosapentaenoic acid), 16,17-EDP (±16,17-epoxy-4*Z*,7*Z*,10*Z*,13*Z*,19*Z*-docosapentaenoic acid), 7,8-EDP (±7,8-epoxy-4*Z*,10*Z*, 13*Z*,16*Z*,19*Z*-docosapentaenoic acid), 13,14-EDP (±13,14-epoxy-4*Z*,7*Z*,10*Z*,16*Z*,19*Z*-docosa- pentaenoic acid), 15-oxoETE (15-oxo-5*Z*,8*Z*,11*Z*,13*E*-eicosatetraenoic acid), 12oxoETE (12-oxo-5*Z*,8*Z*,10*E*,14*Z*-eicosatetraenoic acid), 5-oxoETE (5-oxo-6*E*,8*Z*,11*Z*,14*Z*-eicosatetraenoic acid), 12-HETE-d~8~ (12(*S*)-hydroxy-5*Z*,8*Z*,10*E*,14*Z*-eicosatetraenoic-5,6,8,9,11,12,14,15-d~8~ acid), EPA (5*Z*,8*Z*,11*Z*,14*Z*,17*Z*-eicosapentaenoic acid), DHA (4*Z*,7*Z*,10*Z*,13*Z*,16*Z*,19*Z*-docosahexaenoic acid), and ARA (5*Z*,8*Z*,11*Z*,14*Z*-eicosatetraenoic acid) were purchased from Cayman Chemicals (Ann Arbor, MI, USA). The supplier stated purities higher than 96% for all standards. Methanol and water, Optima LC-MS grade, were purchased from Fisher Scientific (Branchburg, NJ, USA); methyl formate was purchased from Sigma Aldrich (Poole, UK); n-Hexane was provided by Merck (Darmstadt, Germany) and ethanol, formic acid and hydrochloric acid were from AnalR Normapur (Fontenai, France). SPE cartridges (Oasis-HLB, 60 mg, 3 mL) were supplied by Waters (Milford, MA, USA).

3.2. Plasma and Adipose Tissue Samples {#sec3dot2-molecules-24-02276}
--------------------------------------

Blood from Wistar rats from a previous experiment was collected and centrifuged at 850 g (4 °C, 15 min) in the presence of EDTA to remove erythrocytes. Then, plasma was supplemented with 5 mM phenyl methyl sulfonyl fluoride (PMSF, protease inhibitor) and erythrocyte free samples were immediately stored at −80 °C until use. The defrosting process was carried out slowly in darkness, to prevent possible analyte oxidation and degradation \[[@B46-molecules-24-02276]\]. Total abdominal fat, corresponding to the sum of epididymal, perirenal and mesenteric depots was excised, washed with 0.9% NaCl solution, weighed and immediately frozen in liquid nitrogen upon sacrifice.

3.3. Sample Preparation by Solid Phase Extraction {#sec3dot3-molecules-24-02276}
-------------------------------------------------

Lipid mediators from plasma samples were extracted following a modified SPE method previously described \[[@B47-molecules-24-02276]\]. Briefly, 1300 µL of cold methanol: water (30:70, *v*/*v*) was used to extract metabolites from 200 µL of spiked plasma with internal standard 12-HETE-d8 (500 ng/mL). After centrifugation, remaining solution was loaded into conditioned Oasis-HLB cartridges (60 mg, 3 mL, Waters, Milford, MA, USA) with 5 mL methanol (0.5% BHT) and 5 mL water in succession. Then, cartridges were washed with 5 mL cold water, 5 mL cold methanol: water (15:75, *v*/*v*), and 2.5 mL cold hexane in succession. After sorbent dryness, compounds were eluted with 2 mL of cold methyl formate (0.1% BHT). Extracts were evaporated to dryness in a speed-Vacuum system from Supelco (Bellefonte, PA, USA) coupled to a vacuum pump from Millipore (Bedford, MA, USA). The residue was dissolved in 30 µL cold ethanol and stored at −80 °C prior to LC-MS/MS analysis.

Metabolites from adipose tissue were extracted using a modified method of a published protocol \[[@B48-molecules-24-02276]\]. 150 mg of frozen tissues were cut, spiked with internal standard 12-HETE-d8 and extracted by adding 1 mL cold-methanol (0.5% BHT) and sonication for 1min under 0.6 sec cycle and 100% of amplitude (Labsonic sonicator from Sartorius, city, Germany). Samples were incubated on ice for 10 min and then centrifuged at 800 g for 10 min, at 4 °C, to remove potential proteins that may cause interference. Supernatant was transferred to a clean amber glass vial and pellet was subjected to a second extraction in methanol and sonication as described. Both supernatants were collected together and final pellet was washed with 500 µL cold methanol: water (30:70, *v*/*v*) twice. The pooled fractions were diluted with 4.6 mL of cold water to a final solution of methanol: water (30:70, *v*/*v*). Then, samples were loaded to SPE cartridges following the same procedure as plasma samples.

3.4. LC-MS/MS {#sec3dot4-molecules-24-02276}
-------------

Chromatographic separation was carried out on a Dionex UltiMate 3000 Series (Thermo Fisher, Rockford, IL, USA) that includes a binary pump, a degasser system and a thermostated autosampler. Compounds were separated on a C18-Symmetry column, 150 × 2.1 mm, 3.5 μm (Waters) protected with a 4 × 2mm C18 guard cartridge provided by Phenomenex (Torrance, CA, USA). A binary eluent system of water (A) and methanol (B), both with 0.02% (*v*/*v*) of formic acid, was used as mobile phase. The gradient was: 0--1 min (60% B), 2--12 min (80% B), 13--18 min (100% B), and 19--24 min (60% B). The flow rate was set to 0.2 mL/min, the column effluent was directly introduced in the ESI interface without splitting, and injection volume was set to 10 μL. The column was maintained at room temperature and extracts were kept at 4 °C in the autosampler. Mass spectrometry analyses were carried out on a dual-pressure linear ion trap LTQ Velos Pro (Thermo Fisher). Operating conditions of the ESI source were negative ion mode with a sheath gas flow rate of 40 units, spray voltage of 5.5 kV, capillary temperature of 300 °C and S-lens radio-frequency level of 60%. Nitrogen was used as nebulizing gas and helium was the collision gas. Instrument control and data acquisition were done with Xcalibur software. Compounds were divided into 22 groups according to the *m/z* of their parent ion. Acquisition was set as full scan mode ranged from 90 to 400 *m/z* units with the 22 parent masses in a single segment during the whole run. The isolation width was set at 1. Collision energies for each *m/z* are summarized in [Table 5](#molecules-24-02276-t005){ref-type="table"} and they were set as a compromise among the most common used in literature and optimized collision energies for 65 analytical standards used for validation purposes.

3.5. Method Validation: Linearity. Repeatability. Reproducibility. LOD. LOQ. Recovery Experiments. and Matrix Effect {#sec3dot5-molecules-24-02276}
--------------------------------------------------------------------------------------------------------------------

Eight batches of calibration solutions were used to determine the dynamic linear range of response for each of the 65 analytical standards in the range between 1 and 1000 ng/mL, with the exception of ARA. EPA and DHA, whose concentration in biological samples is higher, and thus linearity was evaluated in the range between 0.1 and 50 µg/mL. The calibration curves were calculated using least-squares linear regression. The internal standard (12-HETE-d~8~) was included in all calibration solutions at 500 ng/mL. The reproducibility (inter-day) and repeatability (intra-day) of the instrument was evaluated at three levels of concentration (*n* = 4) for each compound: 1, 50, and 1000 ng/mL; and 0.1, 10, 50 µg/mL for PUFAs, LODs and LOQs were estimated by using signal-to-noise (S/N) ratios of 3 and 10, respectively.

Different recovery experiments were performed to determine global recovery, SPE recovery and matrix effects: (a) The percentage of global recovery was evaluated comparing the signal for each metabolite between: spiked plasma and adipose tissue samples before preparation and a pool of analytical standards at the same level of concentration. (b) The percentage of SPE recovery was determined comparing samples spiked before preparation with samples spiked after the SPE step. (c) Matrix effect was evaluated comparing samples spiked after the SPE extraction with the pool of analytical standards. In any case, when metabolites were already present in blank samples (non-spiked samples), the area of chromatographic peaks in spiked samples was subtracted with the area in blanks. Experiments were done in triplicate and the repeatability of the entire method was expressed as percentage of relative standard deviation (%RSD).

3.6. Qualitative Screening of Samples and Validation {#sec3dot6-molecules-24-02276}
----------------------------------------------------

Plasma and adipose tissue were subjected to SPE-LC-MS/MS. Chromatographic peaks for each parent mass were extracted from MS^2^ selecting quantitative and selective transitions for each lipid mediator according to the fragmentation pattern previously studied. The spectra of each chromatographic peak was studied and compared with the fragmentation pattern to tentatively identify compounds in samples. Then, other samples were spiked before extraction with a pool of 65 standards described in the chemical section. Spiked samples were analyzed under the same LC-MS/MS conditions than non-spiked ones and hypothetical identifications were validated using the information of retention times and fragmentation in standards and samples.

3.7. Data Analysis {#sec3dot7-molecules-24-02276}
------------------

Means, standard deviations, least-squares linear regression curves, and percentages used to validate methodology were performed by using the free R software (version 3.2.4).

4. Conclusions {#sec4-molecules-24-02276}
==============

An extensive study of fragmentation patterns provided fingerprints allowing us to comprehensively elucidate and identify lipid mediators in biological samples obtained by SPE-LC-MS/MS analysis. It has allowed the identification of over 100 bioactive ω-6 and ω-3 metabolites. Interestingly, illustrative fragmentations of EPA and DHA derivatives have been innovatively established for successful identification. The fragmentation patterns study could be used for developing software in order to facilitate the identification of this big family of metabolites without the need of standards for qualitative purposes. The screening method was useful to correctly identify more than 85% of the compounds found in biological samples using the fragmentation patterns here proposed. Moreover, the method allowed the identification of these metabolites without losing information by the use of predefined ions list. Few works proposing MS/MS screening methods to analyze lipid mediators have been found in literature. In our study, we suggested new specific transitions to identify lipid mediators, especially for those derived from EPA and DHA and we achieved a high success score in identifications by using a LIT without the high mass resolution of an Orbitrap. Further improvements of these techniques are needed in order to increase the number of target metabolites that can be accurately identified in a single screening step before the quantitative analysis.
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The following are available online. Supplementary Materials S1: Common and specific transitions suggested for hydroxy-derivates from ARA, EPA and DHA. Product ion spectrum at *m/z* 319 for HETEs, *m/z* 317 for HEPEs, and *m/z* 343 for HDoHEs were obtained from database of *LIPID MAPS* at CID 30V. No spectra was found for 19-HETE. Supplementary Materials S2: Common and specific transitions suggested for 12 and 15 hydroperoxy-derivates of ARA and EPA. Product ion spectrum at *m/z* 335 for HpETEs, and *m/z* 333 for HpEPEs were obtained from database of *LIPID MAPS* at CID 30V. Supplementary Materials S3: Fragmentation pattern suggested for prostaglandins derived from ARA and EPA. Product ion spectrum at *m/z* 331, *m/z* 333, *m/z* 351, and *m/z* 367 were obtained from database of *LIPID MAPS* at CID 30V. Supplementary Materials S4: Possible fragments for identification of RvD~2~, RvD~3~, RvD~4~, RvE~2~, and MaR-1. Supplementary Materials S5: Fragmentation pattern suggested for LxB~4~ (product ion spectrum at *m/z* 351 \[[@B33-molecules-24-02276]\]), and several DiHETEs and DiHETrEs (product ion spectrum at *m/z* 335 and *m/z* 337 obtained from *LIPID MAPS* at CID 30V). MS/MS spectrum was not found for LxA~5~, 8,15-DiHETE, 14,15-DiHETE, and 17,18-DiHETE; thus, possible fragments for identification were suggested based on lipid structure. Supplementary Materials S6: Fragmentation pattern suggested for EpETrE isomers and LTA~4~. Product ion spectrum at *m/z* 319 were obtained from database of *LIPID MAPS* at CID 30V, and *m/z* 317 was obtained from Murphy et al \[[@B33-molecules-24-02276]\]. Supplementary Materials S7: Fragmentation pattern suggested for several keto-PGs. Product ion spectrum at *m/z* 349, *m/z* 351, *m/z* 353, *m/z* 367, and *m/z* 369 were obtained from database of *LIPID MAPS* at CID 30V. Supplementary Materials S8: Fragmentation pattern suggested for TXB~2~ and TXA~2~. The product ion spectrum at and *m/z* 369 was obtained from *LIPID MAPS* at CID 30V. Characteristic MS/MS transitions were suggested for TXA~2~ based on lipid structure.
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ALA

linolenic acid

ARA

arachidonic acid

DGLA

dihomo-γ-linolenic acid

DHA

docosahexaenoic acid

DiHETE

dihydroxyeicosatetraenoic acids

EPA

eicosapentaenoic acid

EpETrE

epoxyeicosatrienoic acid

HDoHE

hydroxydocosahexaenoic acid

HEPE

hydroxyeicosapentanoic acid

HETE

hydroxyeicosatetraenoic acid

HpDoHE

hydroperoxydocosahexaenoic acid

HpEPE

hydroperoxyeicosapentanoic acid

HpETE

hydroperoxyeicosatetraenoic acid

IsoP

isoprostane

k-PG

ketoprostaglandin

LA

linoleic acid

LT

leukotriene

Lx

lipoxin

MaR

maresin

oxoETE

ketohydroxyeicosatetraenoic acid

PD

neuroprotectin

PG

prostaglandin

PUFA

polyunsaturated fatty acid

Rv

resolvin

TX

thromboxane

###### 

(**a**): Cascade of formation of lipid mediators from ω-6 LA, DGLA and ARA. (**b**): Cascade of formation of lipid mediators from ω-3 ALA, EPA, and DHA.
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![Fragmentation patterns suggested for (**a**) ARA, (**b**) EPA and (**c**) DHA hydroxides. Common cleavages and specific transitions for 8-HETE, 12-HEPE and 17-HDoHE. Product ion spectra at *m/z* 319 for 8HETE, *m/z* 317 for 12HEPE, and *m/z* 343 for 17HDoHE were obtained from the LIPID MAPS database at CID 30V.](molecules-24-02276-g002){#molecules-24-02276-f002}

###### 

Fragmentation pattern suggested for (**a**) ARA, (**b**) EPA and (**c**) DHA hydroperoxides. Common cleavages and specific transitions for 5-HpETE, 5-HpEPE, and 17-HpDoHE. Product ion spectra at *m/z* 335 for 5-HpETE, *m/z* 333 for 15-HpEPE, and *m/z* 359 for 17-HpDoHE were obtained from the LIPID MAPS database at CID 30V.

![](molecules-24-02276-g003a)
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###### 

Fragmentation patterns suggested for (**a**) PGE~3~, PGD~3~, (**b**) PGF~2α.~ and (**c**) PGE~2~. Product ion spectra at *m/z* 349, *m/z* 353, and *m/z* 351 were obtained from the LIPID MAPS database at CID 30V. An identical spectrum was found for PGE~3~ and PGD~3.~

![](molecules-24-02276-g004a)

![](molecules-24-02276-g004b)

###### 

Fragmentation patterns suggested for (**a**,**b**) RvD~1~, (**c**) RvE~1.~ and (**d**,**e**) PD~1~. Product ion spectra at *m/z* 375, *m/z* 349 and *m/z* 359 were obtained from the LIPID MAPS database at CID 30V.
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###### 

Fragmentation pattern suggested for (**a**) LxA~4~, (**b**) LTB~4.~ and (**c**) 8.9-DiHETrE. Product ion spectrum at *m/z* 351. *m/z* 335. and *m/z* 337 were obtained from database of LIPID MAPSat CID 30V.
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![Fragmentation pattern suggested for 11.12-EpETrE. The product ion spectrum at m/z 319 was obtained from database of LIPID MAPS at CID 30V.](molecules-24-02276-g007){#molecules-24-02276-f007}

###### 

Fragmentation pattern suggested for (**a**) 12-oxoETE, (**b**) 5-oxoETE, and (**c**) 15-oxoETE (product ion spectrum at *m/z* 317 obtained from LIPID MAPS at CID 30V). A MS/MS spectrum was not found for 15oxoETE, thus, potential fragments for identification were suggested based on lipid structure.
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![Fragmentation pattern suggested for 15k-PGF~2α~. The product ion spectrum at *m/z* 351 was obtained from the LIPID MAPS database at CID 30V.](molecules-24-02276-g009){#molecules-24-02276-f009}

![Fragmentation pattern suggested for TXB~3~. The product ion spectrum at *m/z* 367 was obtained from LIPID MAPS at CID 30V.](molecules-24-02276-g010){#molecules-24-02276-f010}

molecules-24-02276-t001_Table 1

###### 

Retention times. MS/MS quantification transitions (*m/z*). Linearity by least-squares linear regression (1 to 1000 ng/mL except for PUFAs: 0.1 to 50 µg/mL). Intra-day repeatability (*n* = 4) and inter-day reproducibility (*n* = 4) of LC-MS assays at three concentration levels (1-50-1000 ng/mL except for PUFAs: 0.1-10-50 µg/mL). LOD and LOQ of the 65 analytical standards.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound          Retention Time (min)   MS/MS Quantification   Linearity (R^2^)   Repeatability (%RSD)   Reproducibility (%RSD)   LOD\      LOQ (ng/mL)                     
                                                                                                                                     (ng/mL)                                   
  ----------------- ---------------------- ---------------------- ------------------ ---------------------- ------------------------ --------- ------------- ---- ---- ------- -------
  15-HEPE           11.96                  317 \> 247             0.9996             1                      1                        3         11            1    3    0.37    1.24

  18-HEPE           11.55                  317 \> 259             0.9999             7                      1                        1         7             2    3    0.18    0.58

  12-HEPE           12.62                  317 \> 208             1.000              3                      3                        3         6             3    7    0.01    0.03

  5-HEPE            14.17                  317 \> 115             0.9999             3                      0                        2         7             2    8    0.37    1.25

  11-HEPE           12.13                  317 \> 195             0.9995             8                      0                        1         11            1    6    0.13    0.43

  11-HETE           15.32                  319 \> 167             0.9968             4                      4                        8         18            8    9    0.06    0.21

  5-HETE            15.96                  319 \> 115             0.9807             13                     9                        2         14            7    2    0.07    0.24

  12-HETE           15.48                  319 \> 179             0.9991             4                      3                        7         7             7    8    0.03    0.11

  15-HETE           14.83                  319 \> 219             0.9962             12                     2                        4         11            10   4    0.07    0.25

  20-HETE           13.69                  319 \> 245             0.9988             4                      2                        2         11            4    4    0.53    1.76

  4-HDoHE           16.08                  343 \> 281             0.9997             2                      10                       9         14            8    9    0.04    0.15

  17-HDoHE          15.19                  343 \> 245             0.9998             5                      3                        2         10            4    5    0.29    0.96

  14-HDoHE          15.43                  343 \> 205             0.9907             3                      6                        5         6             10   8    0.10    0.33

  11-HDoHE          15.67                  343 \> 149             0.9985             10                     6                        6         9             8    5    0.07    0.25

  15-OxoETE         13.69                  317 \> 113             0.9999             13                     3                        1         13            8    2    1.58    5.27

  12-OxoETE         14.83                  317 \> 153             0.9944             nd                     3                        3         nd            71   27   1.21    4.03

  5-OxoETE          15.95                  317 \> 203             0.9974             7                      9                        5         14            8    4    0.11    0.38

  15-HpEPE          11.93                  333/315 \> 271         0.9986             nd                     2                        2         nd            14   3    0.59    1.95

  12-HpEPE          12.42                  333/315 \> 271         0.9996             10                     1                        1         10            23   9    0.29    0.95

  12-HpETE          15.39                  335/317 \> 153         0.9998             15                     0                        3         15            29   3    0.50    1.65

  5HpETE            15.86                  335/317 \> 155         0.9620             nd                     13                       7         nd            16   9    6.48    21.59

  15-HpETE          14.83                  335/317 \> 113         0.9991             nd                     3                        1         nd            9    1    17.65   58.84

  17-HpDoHE         15.12                  359/341 \> 297         0.9998             13                     1                        3         11            5    3    1.05    3.51

  14.15-DiHETE      8.58                   335 \> 207             0.9998             9                      1                        1         12            1    1    0.53    1.78

  5.15-DiHETE       7.93                   335 \> 235             0.9983             10                     0                        5         15            17   8    0.18    0.61

  5.6-DiHETE        10.56                  335 \> 145             0.9994             1                      3                        2         1             9    5    0.95    3.16

  11.12-DiHETrE     10.68                  337 \> 167             0.9988             3                      1                        3         8             3    2    0.05    0.16

  8.9-DiHETrE       11.66                  337 \> 185             0.9999             5                      2                        1         7             4    8    0.17    0.55

  14.15-DiHETrE     10.03                  337 \> 207             0.9989             7                      2                        4         19            3    4    0.12    0.39

  5.6-DiHETrE       13.87                  337 \> 145             0.9988             5                      3                        2         7             4    3    0.10    0.35

  19.20-DiHDPA      10.60                  361 \> 273             0.9996             5                      0                        1         9             4    4    0.17    0.55

  17.18-DiHETE      8.50                   335 \> 247             0.9989             2                      3                        2         13            6    4    0.46    1.54

  7.17-hydroxiDPA   8.22                   361 \> 263             1.000              14                     2                        3         14            11   9    0.43    1.45

  11.12-EpETrE      16.12                  319 \> 179             0.9890             13                     9                        11        11            7    9    0.17    0.58

  8.9-EpETrE        16.20                  319 \> 155             0.9516             12                     12                       11        23            20   9    0.13    0.42

  14.15-EpETrE      15.80                  319 \> 219             0.9920             11                     15                       7         11            13   6    0.26    0.87

  5.6-EpETrE        16.28                  319 \> 191             0.9950             15                     12                       5         15            65   29   0.41    1.38

  17.18-EpETE       13.85                  317 \> 259             0.9999             2                      1                        6         11            8    9    0.19    0.63

  11.12-EpETE       15.07                  317 \> 179             0.9969             4                      3                        7         9             6    6    0.24    0.81

  14.15-EpETE       14.83                  317 \> 207             0.9987             6                      2                        4         15            12   11   0.27    0.91

  8.9-EpETE         15.32                  317 \> 155             0.9998             19                     3                        6         13            5    5    0.50    1.67

  19.20-EDP         15.84                  343 \> 241             0.9945             11                     5                        6         18            10   14   0.30    0.99

  10.11-EDP         16.08                  343 \> 153             0.9976             2                      6                        8         10            19   12   0.14    0.45

  16.17-EDP         16.00                  343 \> 233             0.9487             11                     7                        3         16            5    7    0.24    0.79

  7.8-EDP           16.24                  343 \> 141             0.9918             7                      6                        7         24            20   11   0.30    0.99

  13.14-EDP         16.00                  343 \> 193             0.9934             14                     14                       12        15            13   22   0.21    0.69

  LTB4              8.50                   335 \> 195             0.9993             4                      3                        4         17            17   11   0.08    0.27

  LTC4              9.05                   624 \> 272             0.9984             10                     3                        6         11            5    5    0.20    0.67

  PGB2              6.62                   333 \> 175             0.9999             13                     2                        1         12            7    9    0.26    0.86

  PGJ2              6.62                   333 \> 175             0.9975             22                     3                        4         22            11   8    0.75    2.51

  PGE2              5.64                   351 \> 251             0.9997             nd                     4                        3         nd            4    2    3.88    12.95

  PGD2              5.64                   351 \> 251             0.9979             nd                     7                        2         2             5    2    4.33    14.45

  PGD3              5.14                   349 \> 313             0.9985             1                      1                        2         1             1    2    0.10    0.30

  PGE3              5.14                   349 \> 313             0.9985             1                      1                        2         1             1    2    0.10    0.30

  8iso-PGF3α        4.97                   351 \> 253             0.9960             7                      4                        3         14            14   16   0.22    0.73

  8iso-PGF2α        5.47                   353 \> 299             0.9936             8                      3                        2         8             3    2    0.06    0.20

  MaR-1             8.09                   359 \> 177             0.9998             5                      2                        5         9             4    4    0.21    0.71

  PDx               7.67                   359 \> 153             0.9984             3                      1                        3         3             3    4    0.05    0.16

  TXB3              5.05                   367 \> 195             0.9981             1                      3                        2         10            4    2    0.06    0.21

  RvD1              6.00                   375 \> 141             0.9958             1                      1                        2         1             1    2    0.02    0.07

  RvD2              5.56                   375 \> 141             0.9988             4                      2                        2         9             7    3    0.12    0.39

  12-HETE-d8        15.43                  326 \> 183                                5                      6                        4         5             6    4    0.002   0.006

  ARA               17.34                  303 \> 259             0.9677             7                      6                        12        7             11   11   1.96    6.53

  EPA               16.92                  301 \> 257             0.9923             13                     15                       8         11            16   12   0.28    0.93

  DHA               17.27                  327 \> 283             0.9925             10                     13                       11        7             10   15   0.18    0.59
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

molecules-24-02276-t002_Table 2

###### 

Repeatability of the SPE-LC-MS assay. Global Recovery (SPE-LC-MS). Extraction recovery (SPE) and matrix effect (LC-MS) for spiked plasma and adipose tissue samples (*n* = 3). n.e. (non-evaluated).

  Compound          %RSD (*n* = 3)   %Global Recovery   %SPE Recovery   %Matrix Effect                      
  ----------------- ---------------- ------------------ --------------- ---------------- ----- ------ ----- ------
  15-HEPE           9                9                  91              87               102   88     88    99
  18-HEPE           7                6                  85              81               107   95     80    85
  12-HEPE           10               6                  84              94               103   94     82    100
  5-HEPE            8                7                  84              64               107   90     79    71
  11-HEPE           2                6                  93              86               115   94     81    92
  11-HETE           18               3                  75              91               93    96     73    95
  5-HETE            15               11                 144             155              113   115    199   122
  12-HETE           3                6                  91              67               97    109    86    58
  15-HETE           5                12                 86              81               101   108    85    75
  20-HETE           9                9                  95              92               107   101    89    91
  4-HDoHE           7                5                  489             442              101   97     494   580
  17-HDoHE          2                9                  84              78               111   78     76    101
  14-HDoHE          9                10                 85              66               101   95     84    70
  11-HDoHE          8                0                  81              81               108   91     75    84
  15-OxoETE         7                8                  87              54               104   92     84    59
  12-OxoETE         3                14                 94              52               107   80     90    65
  5-OxoETE          15               6                  379             294              101   72     344   409
  15-HpEPE          2                9                  17              22               87    89     10    25
  12-HpEPE          0                6                  7               18               29    60     25    33
  12-HpETE          4                21                 27              28               92    90     26    30
  5-HpETE           16               11                 53              71               64    105    83    67
  15-HpETE          0                23                 37              44               57    71     66    67
  17-HpDoHE         3                12                 24              19               86    94     14    21
  14.15-DiHETE      7                10                 95              90               92    93     103   97
  5.15-DiHETE       4                8                  92              86               99    94     94    92
  5.6-DiHETE        12               8                  61              95               75    96     82    99
  11.12-DiHETrE     3                12                 69              35               82    41     83    83
  8.9-DiHETrE       7                18                 82              36               92    42     90    84
  14.15-DiHETrE     2                7                  59              35               91    40     64    85
  5.6-DiHETrE       6                10                 83              34               93    42     88    80
  19.20-DiHDPA      1                15                 78              37               91    41     85    87
  17.18-DiHETE      1                52                 87              59               99    63     88    89
  7.17-hydroxiDPA   1                27                 74              33               89    42     82    79
  11.12-EpETrE      1                19                 447             142              107   45     397   341
  8.9-EpETrE        3                30                 334             121              107   45     309   266
  14.15-EpETrE      9                29                 179             41               114   38     143   145
  5.6-EpETrE        7                20                 228             104              103   38     211   276
  17.18-EpETE       2                22                 86              35               100   50     84    72
  11.12-EpETE       3                13                 78              37               102   45     76    80
  14.15-EpETE       0                16                 70              36               100   44     70    81
  8.9-EpETE         0                21                 69              34               101   47     69    69
  19.20-EDP         4                10                 185             51               134   45     129   110
  10.11-EDP         21               30                 394             159              105   46     396   346
  16.17-EDP         2                17                 469             194              111   53     404   333
  7.8-EDP           10               8                  238             114              108   50     228   237
  13.14-EDP         1                19                 471             191              109   50     433   336
  LTB4              8                7                  82              52               98    96     78    54
  LTC4                                                  0               0                0     0      60    65
  PGB2              2                6                  97              68               115   93     85    73
  PGJ2              5                9                  81              67               97    88     83    76
  PGE2              8                8                  81              82               101   90     80    91
  PGD2              7                67                 128             46               109   94     118   51
  PGD3/PGE3         10               n.e.               94              n.e.             94    n.e.   100   n.e.
  8iso-PGF3α        14               11                 45              33               50    43     103   79
  8iso-PGF2α        8                n.e.               86              n.e.             85    n.e.   102   n.e.
  MaR-1             3                1                  108             73               124   111    87    60
  PDx               12               5                  97              75               102   103    96    74
  TXB3              7                11                 48              36               61    55     78    68
  RvD1              12               n.e.               85              n.e.             75    n.e.   89    n.e.
  RvD2              10               9                  63              56               98    86     64    65
  12-HETE-d8        15               6                  73              60               91    94     76    64
  ARA               4                n.e.               100             n.e.             111   n.e.   90    n.e.
  EPA               6                n.e.               98              n.e.             106   n.e.   93    n.e.
  DHA               3                n.e.               88              n.e.             123   n.e.   71    n.e.
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###### 

Hypothesized specific fragments produced from different isomers of ARA. EPA and DHA hydroperoxides based on the chain position of --OOH group.

  Parent Mass *m/z*   Family           Isomers          Specific Fragments from α-Hydroxy Cleavage *m/z*   Specific Fragments from Diol *m/z*
  ------------------- ---------------- ---------------- -------------------------------------------------- ------------------------------------
  359                 HpDoHE           4-HpDoHE         101\. 99. 71                                       121\. 101. 73
  7-HpDoHE            141\. 139. 111   161\. 141. 113                                                      
  8-HpDoHE            153\. 151. 123   173\. 153. 125                                                      
  10-HpDoHE           181\. 179. 151   201\. 181. 153                                                      
  13-HpDoHE           221\. 219. 191   241\. 221. 193                                                      
  14-HpDoHE           233\. 231. 203   253\. 233. 205                                                      
  16-HpDoHE           261\. 259. 231   281\. 261. 233                                                      
  20-HpDoHE           313\. 311. 283   333\. 313. 285                                                      
  333                 HpEPE            8-HpEPE          155\. 153. 125                                     175\. 155. 127
  9-HpEPE             167\. 165. 137   187\. 167. 139                                                      
  11-HpEPE            195\. 193. 165   213\. 193. 165                                                      
  18-HpEPE            287\. 285. 257   307\. 287. 259                                                      
  335                 HpHETE           8-HpETE          155\. 153. 125                                     175\. 155. 127
  9-HpETE             167\. 165. 137   187\. 167. 139                                                      
  11-HpETE            195\. 193. 165   213\. 193. 165                                                      
  19-HpETE            303\. 301. 273   321\. 301. 273                                                      
  20-HpETE            317\. 315. 287   335\. 315. 287                                                      
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###### 

Compounds tentatively identified in adipose tissue and plasma, validation with standards and specific transitions used for our hypothetical identifications.

  ---------------------- ---------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------- ------------------
  **Parent Ion *m/z***   **Identified Compounds in Adipose Tissue**           **Identified Compounds in Plasma**                       **Specific Transitions *m/z*** (Most Intense-Non Specific)                                                            
                         **Screening Analysis** (Hypothetic Identification)   **Validation with Standards** (Confirmation/Rejection)   **Screening Analysis** (Hypothetic Identification)           **Validation with Standards** (Confirmation/Rejection)   
  **317**                18-HEPE                                              confirmation                                             18-HEPE                                                      confirmation                                             287\. 259
  15-HEPE                confirmation                                         15-HEPE                                                  confirmation                                                 247\. 219                                                
  12-HEPE                confirmation                                         12-HEPE                                                  confirmation                                                 207\. 179                                                
  11-HEPE                confirmation                                         11-HEPE                                                  confirmation                                                 195\. 167                                                
  9-HEPE                                                                                                                                                                                            167\. 139                                                
  5-HEPE                 confirmation                                         5-HEPE                                                   confirmation                                                 115\. 87                                                 
  12-oxoETE              confirmation                                         12-oxoETE                                                confirmation                                                 207\. 179. (153)                                         
  15-oxoETE              rejection                                                                                                                                                                  247\. 219. (113)                                         
  5-oxoETE               rejection                                            5-oxoETE                                                 rejection                                                    115\. 87. (203)                                          
  319                                                                                                                                  20-HETE                                                      confirmation                                             317\. 289. (245)
  15-HETE                confirmation                                         15-HETE                                                  confirmation                                                 247\. 219                                                
  12-HETE                confirmation                                         12-HETE                                                  confirmation                                                 207\. 179                                                
  11-HETE                confirmation                                         11-HETE                                                  confirmation                                                 195\. 167                                                
  5-HETE                 rejection                                            5-HETE                                                   rejection                                                    115\. 87                                                 
  5.6-EpETrE             confirmation                                         5.6-EpETrE                                               confirmation                                                 115\. 87                                                 
  11.12-EpETrE           confirmation                                                                                                                                                               207\. 179. 167                                           
  14.15-EpETrE           confirmation                                         14.15-EpETrE                                             confirmation                                                 249\. 221. 207                                           
  343                    20-HDoHE                                                                                                      20-HDoHE                                                                                                              313\. 285. (187)
  17-HDoHE               confirmation                                         17-HDoHE                                                 confirmation                                                 273\. 245                                                
  16-HDoHE                                                                                                                                                                                          261\. 233                                                
  14-HDoHE               confirmation                                         14-HDoHE                                                 confirmation                                                 233\. 205                                                
  13-HDoHE                                                                    13-HDoHE                                                                                                              221\. 193                                                
  11-HDoHE               confirmation                                                                                                                                                               193\. 165. (149)                                         
                                                                              10-HDoHE                                                                                                              181\. 153                                                
  8-HDoHE                                                                                                                                                                                           153\. 125. (189). (109)                                  
  4-HDoHE                confirmation                                         4-HDoHE                                                  confirmation                                                 115\. 101. 73                                            
  359-341                                                                     17HpDoHE                                                                                                              17HpDoHE                                                 297
  335                    8.15-DiHETE                                                                                                                                                                                                                         265\. 155
  14.15-DiHETE           confirmation                                         14.15-DiHETE                                             confirmation                                                 265\. 219. 247. 207                                      
  5.12-DiHETE=LTB4       rejection                                            5.12-DiHETE=LTB4                                         rejection                                                    195\. 129                                                
  11.18-DiHETE                                                                11.18-DiHETE                                                                                                          289\. 165. 193                                           
  5.6-DiHETE             confirmation                                         5.6-DiHETE                                               confirmation                                                 115\. (145)                                              
  11.12-DiHETE                                                                11.12-DiHETE                                                                                                          234\. 222. 193. 165                                      
  333-315                                                                                                                              12-HpEPE                                                     confirmation                                             207\. 227. 179
  351                    PGE2-PGD2                                            confirmation                                             PGE2-PGD2                                                    confirmation                                             251
  303                    ARA                                                  confirmation                                             ARA                                                          confirmation                                             259
  301                    EPA                                                  confirmation                                             EPA                                                          confirmation                                             257
  327                    DHA                                                  confirmation                                             DHA                                                          confirmation                                             283
  337                    14-15DiHETrE                                         confirmation                                                                                                                                                                   207\. 129
  ---------------------- ---------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------- ------------------
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###### 

MS/MS conditions of the non-targeted LC-MS/MS method developed. More than 100 compounds were classified in 22 groups according to the *m/z* of their parent ions in negative ESI. Compromise collision energies used for each *m/z* are shown. The families of lipid mediators studied in each parent mass of the method are indicated as well as some examples of metabolites.

  Parent Mass (*m/z*)   Collision Energy (V)          Family of Lipid Mediators   Some Examples
  --------------------- ----------------------------- --------------------------- ----------------------------
  301.0                 25                            PUFAs-ω3                    EPA
  303.0                 30                            PUFAs-ω6                    ARA
  317.0                 28                            HEPEs                       5-HEPE. 8-HEPE. 12-HEPE
  EpETEs                17.18-EpETE                                               
  oxoETEs               12-oxoETE. 5-oxoETE                                       
  LTs                   LTA4                                                      
  319.0                 30                            HETEs                       9-HETE. 11-HETE. 15-HETE
  EpETrEs               11.12-EpETrE. 14.15-EpETrE                                
  326.0                 27                            internal standard           12-HETE-d8
  327.0                 27                            PUFA-ω3                     DHA
  331.0                 30                            PGs                         PGA3. PGB3
  333.0 & 315.0         27                            HpEPEs                      5-HpEPE. 12-HpEPE
  333.0                 27                            Rvs                         RvE2
  PGs                   PGJ2. PGB2                                                
  335.0 & 317.0         30                            HpETEs                      11-HpETE. 12-HpETE
  335.0                 30                            DiHETEs                     5.12-DiHETE. 17.18-DiHETE
  337.0                 30                            DiHETrEs                    11.12-DiHETrE. 8.9-DiHETrE
  343.0                 28                            EDPs                        10.11-EDP
  HDoHEs                4-HDoHE. 17-HDoHE. 20-HDoHE                               
  349.0                 30                            PGs. k-PGs                  PGD3. PGE3. 15k-PGE2
  Rvs                   RvE1                                                      
  LXs                   LXA5                                                      
  351.0                 28                            PGs. k-PGs                  PGE2. PGF3α. 15k-PGF2α
  TXs                   TXA2                                                      
  LXs                   LXA4. LXB4                                                
  353.0                 30                            PGs. k-PGs                  PGF2α. 15k-PGF1α
  359.0 & 341.0         26                            HpDoHEs                     4-HpDoHE. 17-HpDoHE
  359.0                 26                            PDs                         PDx
  MaRs                  7-MaR1                                                    
  361.0                 28                            DiHDPAs                     19.20-DiHDPA
  367.0                 20                            PGs. k-PGs                  PGG2. 6k-PGE1
  TXs                   TXB3                                                      
  369.0                 30                            TXs                         TXB2
  k-PGs                 6k-PGF1α                                                  
  375.0                 27                            Rvs                         RvD1. RvD2
  624.0                 26                            LTs                         LTC4
